Hussein Tawbi, MD
Internal Medicine · Houston, TXNPI 1982729422
Payments from drug & device makers
Across 330 payments — averaging $38,031 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6M
- Merck$5.4M
- Novartis$891K
- GSK$120K
- Regeneron$19K
- Array Biopharma Inc$17K
- plus $49K from 15 others
Across 35 payments — averaging $973.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$15K
- Pfizer$9K
- Regeneron$4K
- Novartis$3K
- Merck$3K
- Novartis Pharma AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 85 | $6,048,403 |
| Merck | 151 | $5,405,200 |
| Novartis | 30 | $891,460 |
| GSK | 1 | $120,000 |
| Regeneron | 17 | $18,609 |
| Array Biopharma Inc | 14 | $17,036 |
| Bristol Myers Squibb | 2 | $9,507 |
| F. Hoffmann-la Roche AG | 7 | $6,669 |
| Pfizer | 3 | $6,092 |
| Karyopharm Therapeutics Inc. | 1 | $5,000 |
| Immunocore Limited | 2 | $4,738 |
| Eisai CO., LTD. | 2 | $3,750 |
| Genentech, Inc. | 1 | $3,465 |
| Eisai Inc. | 2 | $3,281 |
| Novartis Pharma AG | 2 | $3,112 |
| Genentech USA, Inc. | 1 | $1,980 |
| Jazz Pharmaceuticals Inc. | 1 | $1,240 |
| Clinigen, Inc. | 2 | $290 |
| Taiho Oncology, Inc. | 4 | $172 |
| Exelixis Inc. | 1 | $127 |
| Biontech SE | 1 | $49 |
How this compares
$12,550,181 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hans LeeHouston$11.7M
- Dominick DaunnoHouston$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.